These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 25515070)

  • 1. Mendelian randomisation applied to drug development in cardiovascular disease: a review.
    Mokry LE; Ahmad O; Forgetta V; Thanassoulis G; Richards JB
    J Med Genet; 2015 Feb; 52(2):71-9. PubMed ID: 25515070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mendelian randomisation in cardiovascular research: an introduction for clinicians.
    Bennett DA; Holmes MV
    Heart; 2017 Sep; 103(18):1400-1407. PubMed ID: 28596306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mendelian randomization studies on atherosclerotic cardiovascular disease: evidence and limitations.
    Hu Q; Hao P; Liu Q; Dong M; Gong Y; Zhang C; Zhang Y
    Sci China Life Sci; 2019 Jun; 62(6):758-770. PubMed ID: 31104264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mendelian randomization: how genetics is pushing the boundaries of epidemiology to identify new causes of heart disease.
    Thanassoulis G
    Can J Cardiol; 2013 Jan; 29(1):30-6. PubMed ID: 23199790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenomics to Revive Drug Development in Cardiovascular Disease.
    Dubé MP; de Denus S; Tardif JC
    Cardiovasc Drugs Ther; 2016 Feb; 30(1):59-64. PubMed ID: 26768480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mendelian Randomization for the Identification of Causal Pathways in Atherosclerotic Vascular Disease.
    Jansen H; Lieb W; Schunkert H
    Cardiovasc Drugs Ther; 2016 Feb; 30(1):41-9. PubMed ID: 26791863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From genome-wide association studies to Mendelian randomization: novel opportunities for understanding cardiovascular disease causality, pathogenesis, prevention, and treatment.
    Benn M; Nordestgaard BG
    Cardiovasc Res; 2018 Jul; 114(9):1192-1208. PubMed ID: 29471399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development.
    Holmes MV; Richardson TG; Ference BA; Davies NM; Davey Smith G
    Nat Rev Cardiol; 2021 Jun; 18(6):435-453. PubMed ID: 33707768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Aiming for zero blindness].
    Nakazawa T
    Nippon Ganka Gakkai Zasshi; 2015 Mar; 119(3):168-93; discussion 194. PubMed ID: 25854109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sex-specific Mendelian randomisation to assess the causality of sex differences in the effects of risk factors and treatment: spotlight on hypertension.
    de Ruiter SC; Schmidt AF; Grobbee DE; den Ruijter HM; Peters SAE
    J Hum Hypertens; 2023 Aug; 37(8):602-608. PubMed ID: 37024639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mendelian randomisation and the goal of inferring causation from observational studies in the vision sciences.
    Plotnikov D; Guggenheim JA
    Ophthalmic Physiol Opt; 2019 Jan; 39(1):11-25. PubMed ID: 30628743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mendelian randomization suggests non-causal associations of testosterone with cardiometabolic risk factors and mortality.
    Haring R; Teumer A; Völker U; Dörr M; Nauck M; Biffar R; Völzke H; Baumeister SE; Wallaschofski H
    Andrology; 2013 Jan; 1(1):17-23. PubMed ID: 23258625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using Genetic Variants in the Targets of Lipid Lowering Therapies to Inform Drug Discovery and Development: Current and Future Treatment Options.
    Ference BA
    Clin Pharmacol Ther; 2019 Mar; 105(3):568-581. PubMed ID: 29953581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using genetic association data to guide drug discovery and development: Review of methods and applications.
    Burgess S; Mason AM; Grant AJ; Slob EAW; Gkatzionis A; Zuber V; Patel A; Tian H; Liu C; Haynes WG; Hovingh GK; Knudsen LB; Whittaker JC; Gill D
    Am J Hum Genet; 2023 Feb; 110(2):195-214. PubMed ID: 36736292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mendelian Randomization Studies Promise to Shorten the Journey to FDA Approval.
    Roberts R
    JACC Basic Transl Sci; 2018 Oct; 3(5):690-703. PubMed ID: 30456340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nature as a Trialist?: Deconstructing the Analogy Between Mendelian Randomization and Randomized Trials.
    Swanson SA; Tiemeier H; Ikram MA; Hernán MA
    Epidemiology; 2017 Sep; 28(5):653-659. PubMed ID: 28590373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mendelian randomization and estimation of treatment efficacy for chronic diseases.
    Schooling CM; Freeman G; Cowling BJ
    Am J Epidemiol; 2013 May; 177(10):1128-33. PubMed ID: 23585329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leveraging human genetics to guide drug target discovery.
    Stitziel NO; Kathiresan S
    Trends Cardiovasc Med; 2017 Jul; 27(5):352-359. PubMed ID: 27686272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic risk factors and Mendelian randomization in cardiovascular disease.
    Swerdlow DI; Hingorani AD; Humphries SE
    Curr Cardiol Rep; 2015 May; 17(5):33. PubMed ID: 25894797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mendelian randomization studies: a review of the approaches used and the quality of reporting.
    Boef AG; Dekkers OM; le Cessie S
    Int J Epidemiol; 2015 Apr; 44(2):496-511. PubMed ID: 25953784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.